A thioredoxin reductase inhibitor ethaselen induces growth inhibition and apoptosis in gastric cancer

Citations Over TimeTop 19% of 2020 papers

Abstract

Gastric cancer (GC) is the third leading cause of cancer deaths worldwide. Conventional chemotherapy has been proven useful to only a portion of the patients. Previous developed targeted drugs are more effective and tolerable than conventional drugs. Thus the development of novel drugs targeting markers is an urgent task and the main direction for future research. Ethaselen, an inhibitor of thioredoxin reductase (TrxR), has been considered an important anticancer target drug. Previous studies show that it is effective on treating many kinds of cancers. In this paper, we examined that ethaselen effectively inhibited the growth of gastric cancer cells and promoted apoptosis. Organoids were cultured from patient-derived cells in a three-dimension form which are widely used in cancer research to help us understand cancer cells behavior at the sub-organ level and develop novel drugs. We established a drug testing and screening system using GC-derived organoids by recapitulating tumor microenvironment. We confirmed that the TrxR-targeting ethaselen could be a novel and effective drug for gastric cancer treatment.

Related Papers

• → Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs(2009)580 cited
• Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia.(1997)
• → The Thioredoxin System: A Promising Target for Cancer Drug Development(2020)97 cited
• → The logic of kinetic regulation in the thioredoxin system(2011)43 cited
• Selenium and the thioredoxin redox system: effects on cell growth and death.(1997)